Investors
Listed on the Canadian Securities Exchange (CSE): COOL & OTC Markets (OTC): CLABF. Frankfurt: LD62, WKN: A2P8K3
Highlights
Delivery system
- Patent Pending Sublingual Transmucosal Thinstrip Technology
- Administer Psychedelic Compounds, Delivery Mechanisms & Protocols, and Novel Drug Formulations.
R&D
- Patent Pending Biosynthetic Psilocybin
- *cGMP API Grade
- Under One of Few Health Canada Licensed Dealer Labs
*Good Manufacturing Practices Active Pharmaceutical Ingredient
Clinics
- Access To 200,000 + Patients
- Advancement of Psychedelic Treatments through Clinical Research
- Goal to Establish New Locations
Opportunity
- Well Funded
- $20M of Invested Capital
- New Highly Experienced And Reputable Management Team
Trading Chart
Profile
| CUSIP | 21872J |
| ISIN | CA21872J2083 |
| Incorporated | BC / Dec 3 2019 |
| Fiscal Year End | Dec 31 |
| Industry | Junior industrial |
Consultants
Legal Counsel
Cassels
Auditor
Dale Matheson, Carr-Hilton Labonte LLP
Transfer Agent
Computershare Trust Company of Canada